Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
Iduronate 2-sulfatase (IDS) is a sulfatase enzyme associated with Hunter syndrome. Iduronate 2-sulfatase is required for the lysosomal degradation of heparan sulfate and dermatan sulfate. Mutations in this X-chromosome gene that result in enzymatic deficiency lead to Hunter syndrome.
The IDS – Drugs In Development research report provides a comprehensive overview on the therapeutics under development for IDS, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for IDS and features dormant and discontinued projects.
Key Therapy Areas in the IDS Pipeline Drugs Market
The key therapy areas in the IDS pipeline drugs market are Genetic Disorders, and Central Nervous System.
IDS Pipeline Drugs Market, by Therapy Areas
For more target insights, download a free report sample
Key MoA in the IDS Pipeline Drugs Market
The key mechanisms of action in the IDS pipeline drugs market are Iduronate 2 Sulfatase Activator, and Iduronate 2 Sulfatase Replacement.
IDS Pipeline Drugs Market, by MoA
To get more insights on key MoA, download a free sample report
IDS Pipeline Drugs Market Segmentation by RoA
The key routes of administration in the IDS pipeline drugs market are Subcutaneous, Intravenous, Intracerebral, Intracisternal, Intrathecal, and Parenteral.
IDS Pipeline Drugs Market Analysis, by RoA
To get more insights on key RoA, download a free sample report
Key Molecule Types in the IDS Pipeline Drugs Market
The key molecule types in the IDS pipeline drugs market are Recombinant Enzyme, Fusion Protein, Gene Modified Cell Therapy, and Gene Therapy among others.
IDS Pipeline Drugs Market, by Molecule Type
To get more insights on key molecule types, download a free sample report
Major Companies in the IDS Pipeline Drugs Market
The major companies in the IDS pipeline drugs market are GC Pharma, Homology Medicines Inc, RegenxBio Inc, AVROBIO Inc, AngioChem Inc, Bioasis Technologies Inc, Esteve Pharmaceuticals SA, and Takeda Pharmaceutical Co Ltd among others.
IDS Pipeline Drugs Market, by Major Companies
For more company insights, download a free sample report
IDS Pipeline Drugs Market Overview
Key Therapy Areas | Genetic Disorders, and Central Nervous System |
Key Mechanisms of action | Iduronate 2 Sulfatase Activator, and Iduronate 2 Sulfatase Replacement |
Key Routes of Administration | Subcutaneous, Intravenous, Intracerebral, Intracisternal, Intrathecal, and Parenteral |
Key molecule types | Recombinant Enzyme, Fusion Protein, Gene Modified Cell Therapy, and Gene Therapy |
Major companies | GC Pharma, Homology Medicines Inc, RegenxBio Inc, AVROBIO Inc, AngioChem Inc, Bioasis Technologies Inc, Esteve Pharmaceuticals SA, and Takeda Pharmaceutical Co Ltd |
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of IDS
- The pipeline guide reviews pipeline therapeutics for IDS by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in IDS therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates IDS therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA), and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews the latest news related to pipeline therapeutics for IDS
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with a potentially strong product portfolio and create effective counter-strategies to gain a competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for IDS
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and their most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding IDS pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from the pipeline.
AVROBIO Inc
Bioasis Technologies Inc
Denali Therapeutics Inc
Esteve Pharmaceuticals SA
GC Pharma
Homology Medicines Inc
Immusoft Corp
JCR Pharmaceuticals Co Ltd
RegenxBio Inc
Sigilon Therapeutics Inc
Takeda Pharmaceutical Co Ltd
Table of Contents
Table
Figures
Frequently asked questions
-
What are the key therapy areas in the IDS pipeline drugs market?
The key therapy areas in the IDS pipeline drugs market are Genetic Disorders, and Central Nervous System.
-
What are the key mechanisms of action in the IDS pipeline drugs market?
The key mechanisms of action in the IDS pipeline drugs market are Iduronate 2 Sulfatase Activator, and Iduronate 2 Sulfatase Replacement.
-
What are the key routes of administration in the IDS pipeline drugs market?
The key routes of administration in the IDS pipeline drugs market are Subcutaneous, Intravenous, Intracerebral, Intracisternal, Intrathecal, and Parenteral.
-
What are the key molecule types in the IDS pipeline drugs market?
The key molecule types in the IDS pipeline drugs market are Recombinant Enzyme, Fusion Protein, Gene Modified Cell Therapy, and Gene Therapy.
-
What are the major companies in the IDS pipeline drugs market?
The major companies in the IDS pipeline drugs market are GC Pharma, Homology Medicines Inc, RegenxBio Inc, AVROBIO Inc, AngioChem Inc, Bioasis Technologies Inc, Esteve Pharmaceuticals SA, and Takeda Pharmaceutical Co Ltd.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.